- Home
- LOMA vs IOVA Comparison
LOMA vs IOVA Comparison
Compare LOMA & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOMA | IOVA |
|---|---|---|
| Founded | 1926 | 2007 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2017 | 2008 |
Fundamental Metrics
Financial Performance| Metric | LOMA | IOVA |
|---|---|---|
| Price | $11.10 | $3.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $15.00 | $9.11 |
| AVG Volume (30 Days) | 450.9K | ★ 15.0M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.53 | $51.55 |
| Revenue Next Year | N/A | $37.55 |
| P/E Ratio | $187.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.04 | $1.64 |
| 52 Week High | $14.17 | $5.63 |
Technical Indicators
Market Signals| Indicator | LOMA | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 44.57 |
| Support Level | $10.59 | $2.02 |
| Resistance Level | $12.33 | $4.34 |
| Average True Range (ATR) | 0.49 | 0.25 |
| MACD | 0.13 | -0.10 |
| Stochastic Oscillator | 90.65 | 21.47 |
Price Performance
Historical ComparisonAbout LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.